Adjuvant trial in melanoma patients comparing rIFN- to rIFN- to Iscador to a control group after curative resection of high risk primary (≥ 3MM) or regional lymphnode metastasis (EORTC 18871). - Kleeberg,U.R. (European Journal of Cancer, 1999)